Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | MPO | P05164 | 2/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9156094 | 1.00 | ACHE (0.56) | ACHESMN1; SMN2MEN1KMT2ACHRM2 | |
| Hydrochloric Acid SCHEMBL3963988 | 0.98 | ACHE (0.55) | ACHESMN1; SMN2MEN1KMT2ACHRM2 | |
| Hydrochloric Acid SCHEMBL3964021 | 0.98 | ACHE (0.55) | ACHESMN1; SMN2MEN1KMT2ACHRM2 | |
| Hydrochloric Acid SCHEMBL3963138 | 0.98 | ACHE (0.55) | ACHESMN1; SMN2MEN1KMT2ACHRM2 | |
| SCHEMBL13975424 | 0.93 | ACHE (0.52) | ACHESMN1; SMN2MEN1KMT2ACHRM2 | |
| SCHEMBL4630473 | 0.86 | ACHE (0.48) | ACHESMN1; SMN2MPO | |
| SCHEMBL16224920 | 0.86 | SMN1; SMN2 (0.51) | ACHESMN1; SMN2MEN1KMT2ACHRM2 | |
| SCHEMBL22332643 | 0.86 | SMN1; SMN2 (0.51) | ACHESMN1; SMN2MEN1KMT2ACHRM2 | |
| SCHEMBL14303982 | 0.81 | ACHE (0.52) | ACHESMN1; SMN2CHRM2MPO | |
| SCHEMBL20354426 | 0.80 | MEN1 (0.59) | ACHESMN1; SMN2MEN1KMT2ACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517883-B8 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2008-05-21 | — | — | EP | disclosed |
| US-7355069-B2 | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | disclosed |
| US-7351858-B2 | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | ASTRAZENECA AB (SE) | 2008-04-01 | — | — | US | disclosed |
| EP-1517679-B1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2008-02-13 | — | — | EP | disclosed |
| EP-1517883-B1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2008-02-13 | — | — | EP | disclosed |
| US-20050256198-A1 | Ortho-substituted benzoic acid derivatives for the treatmetn of insulin resistance | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| US-20050222261-A1 | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | ASTRAZENECA AB, R&D HEADQUARTERS, GLOBAL INTELLECTUAL PROPERTY PATENTS (SE) | 2005-10-06 | — | — | US | disclosed |
| EP-1517883-A1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | AstraZeneca AB (SE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000790-A1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222261-A1 | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | INSR, GPR119, IRS1 | ACHE 3839/4885SMN1; SMN2 2324/4885MEN1 1285/4885 |
| US-20050256198-A1 | Ortho-substituted benzoic acid derivatives for the treatmetn of insulin resistance | GPR119, INSR, IRS1 | ACHE 4063/4885SMN1; SMN2 1355/4885MEN1 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.